Ph3 PMO Fracture Study ALN SupVert
Research payments
$816,023
Through program year 2024, $816,023 in research payments was reported against Ph3 PMO Fracture Study ALN SupVert, across 19 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $21,269 | 4 |
| 2021 | Research | $8,672 | 2 |
| 2020 | Research | $9,891 | 7 |
| 2019 | Research | $776,191 | 6 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Felicia Cosman West Haverstraw, NY Named on 3 payments
- Edward Lewiecki Albuquerque, NM Named on 3 payments
- Roberto Civitelli Saint Louis, MO Named on 2 payments
- Robert Feldman Laguna Hills, CA Named on 2 payments
- Paul Miller Golden, CO Named on 2 payments
- Michelle Odonoghue Boston, MA Named on 1 payment
- Christopher Recknor Gainesville, GA Named on 1 payment
- Marc Sabatine Boston, MA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.